The incidence of dyslipidemia in a sample of asymptomatic probands established by the means of Lipoprint system

Česká verzia

Authors: A. Dukát ¹; S. Oravec ¹; M. Wawruch ²; P. Gavornik ¹; P. Sabaka ¹
Authors place of work: II. interná klinika Lekárskej fakulty UK a UN Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC ¹; Ústav farmakológie Lekárskej fakulty UK Bratislava, prednostka prof. MUDr. Viera Kristová, CSc. ²
Published in the journal: Vnitř Lék 2011; 57(3): 258-260
Category: 60th birthday of prof. Mudr. Jiřího Vítovce, CSc, FESC

Summary

Method of lipoprotein determination on polyamideacryl gel Lipoprint enables an exact quantification nonatherogenic and atherogenic plasma lipoproteins. For its use in human medicine this method was recently approved by FDA. According to majority of nonatherogenic, or atherogenic lipoproteins in their spectrum this method can distinguish nonatherogenic type A vs atherogenic type B. After their identification, there is the possibility for exact means of interventions among patients with higher cardiovascular risk. Also in the group of clinically healthy asymptomatic controls with normolipemia it is possible using this method to estimate the certain group of risk of development of premature atherothrombosis.

Key words:
cardiovascular diseases – diagnostics – dyslipoproteinaemias – therapy

Zdroje

1. Češka R, Krutská L, Zlatohlávek L et al. Komplexní léčba kardiovaskulárního rizika. Zaměřeno na telmisartan. Vnitř Lék 2010; 56: 839–844.

2. Rosolová H, Petrlová B, Šimon J et al. Makrovaskulární a mikrovaskulární komplikace u diabetiků 2. typu. Vnitř Lék 2008; 54: 229–237.

3. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

4. Widimský J. Jaké jsou optimální hodnoty systolického tlaku u diabetiků? Studie ACCORD Blood Pressure dokončena. Cor Vasa 2010; 52: 700–705.

5. Oravec S. Nová laboratórno-medicínska pomoc v diagnostike dyslipoproteinémií a kardiovaskulárnych ochorení: Identifikácia LDL podskupín. Med Milit Slov 2006; 8: 28–32.

6. Oravec S. Den drohenden Herztod erkennen – und vermeidem. Der Mediziner 2010; 4: 6–7.

7. Oravec S, Dukát A, Gavorník P et al. Lipoproteínový profil séra pri novozistenej artériovej hypertenzii. Úloha aterogénnych lipoproteínov v patogenéze ochorenia. Vnitř Lék 2010; 56: 967–971.

8. Kučera M, Oravec S, Očadlík I. Význam fenofibrátu v liečbe aterogénnej dyslipoproteinémie. Vnitř Lék 2010; 56: 865–870.

9. Shoji T, Hatsuda S, Tsuchikura S et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582–588.

10. Vaverková H, Karásek D, Jackuliaková D et al. Klasifikace dyslipidemií založená na koncentraci apolipoproteinu B a triglyceridú. Vnitř Lék 2010; 56: 889–892.

11. Van J, Pan J, Charles MA et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679–1685.

12. Assmann G, Cullen P, Schulte H. Non-LDL related dyslipidaemia and coronary risk: a case-control study. Diab Vasc Dis Res 2010; 7: 204–212.

13. Carey VJ, Bishop L, Laranjo N et al. Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Lown-Density Lipoprotein Cholesterol Control. Am J Cardiol 2010; 106: 757–763.

14. Souček M, Kára T et al. Klinická patofyziologie hypertenze. Praha: Grada Publishing 2002.

15. Fruchart JC, Sacks FM, Hermans MP et al. Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Iniciative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008; 5: 319–335.

16. Fábryová Ľ. Manažment aterogénnej dyslipidémie pri metabolickom syndróme. Via Pract 2007; S4: 13–18.

17. Berger JS, Jordan CO, Lloyd-Jones D et al. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010; 55: 1169–1177.